T. Rowe Price Investment Management, Inc. has significantly increased its investment in Cabaletta Bio, Inc., raising its ownership to 13.1%. This move is notable as it reflects the investment firm's confidence in Cabaletta's potential within the biological products industry.

Cabaletta Bio, Inc. is a company focused on biological products, particularly in the field of innovative therapies. The recent filing, dated November 6, 2026, indicates that T. Rowe Price now holds 28,138,417 shares of Cabaletta, which translates to a substantial voting power of 28,048,173 shares.

Background

T. Rowe Price Investment Management, Inc. is a Maryland-based investment management firm. It is known for its strategic investments across various sectors. The company filed its latest report under Schedule 13G/A with the SEC, reflecting its ongoing commitment to investing in promising companies.

The filing indicates T. Rowe Price's beneficial ownership of Cabaletta Bio, which is classified under the SIC code for biological products. This sector is characterized by companies that develop and manufacture biological products, excluding diagnostic substances.

What the Filing Says

The filing states, "T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied." This highlights the firm's approach to managing its investments while maintaining compliance with SEC regulations.

Impact

This increase in ownership may have implications for both T. Rowe Price and Cabaletta Bio. For T. Rowe Price, it solidifies its position as a significant stakeholder in Cabaletta, potentially influencing company decisions. For Cabaletta Bio, the increased investment may enhance its credibility and attract further interest from other investors.

What's Next

The filing does not specify what happens next regarding T. Rowe Price's investment strategy or any potential future actions related to Cabaletta Bio.